Strategic Wealth Partners Ltd. Increases Position in Stryker Co. (NYSE:SYK)

Strategic Wealth Partners Ltd. increased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 25.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,345 shares of the medical technology company's stock after acquiring an additional 4,671 shares during the quarter. Strategic Wealth Partners Ltd.'s holdings in Stryker were worth $9,066,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Oak Thistle LLC bought a new stake in Stryker in the 4th quarter valued at $271,000. Ritholtz Wealth Management lifted its holdings in shares of Stryker by 3.5% during the fourth quarter. Ritholtz Wealth Management now owns 5,322 shares of the medical technology company's stock worth $1,916,000 after buying an additional 182 shares in the last quarter. Capital & Planning LLC boosted its position in shares of Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after acquiring an additional 29 shares during the period. Everpar Advisors LLC grew its stake in shares of Stryker by 7.0% in the fourth quarter. Everpar Advisors LLC now owns 701 shares of the medical technology company's stock valued at $252,000 after acquiring an additional 46 shares in the last quarter. Finally, Procyon Advisors LLC increased its position in Stryker by 2.1% during the fourth quarter. Procyon Advisors LLC now owns 2,552 shares of the medical technology company's stock worth $919,000 after acquiring an additional 53 shares during the period. Institutional investors own 77.09% of the company's stock.

Stryker Trading Down 1.4%

Shares of SYK stock traded down $5.39 on Tuesday, hitting $389.30. The company had a trading volume of 1,047,447 shares, compared to its average volume of 1,346,784. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market cap of $148.59 billion, a P/E ratio of 50.17, a P/E/G ratio of 2.93 and a beta of 0.93. The stock's 50-day moving average is $367.75 and its two-hundred day moving average is $375.89.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.50 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker's payout ratio is 45.41%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

SYK has been the topic of a number of analyst reports. Wells Fargo & Company increased their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Evercore ISI reduced their price target on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Sanford C. Bernstein set a $450.00 target price on Stryker in a report on Monday, May 5th. Finally, Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $427.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.